

Q2
Sub
cancel
native CD34 [polypeptide; or

b) an antibody capable of binding a native CD34].

In claim 8, line 1, please cancel "6" and replace it with --1--; line 5, delete "or"; and line 6, add --or rheumatoid arthritis-- after "toxicity".

Please amend claim 9 as follows:

9. (Amended) The method of claim [2] 1 further comprising the administration of a therapeutically effective amount of a compound selected from the group consisting of:

- Q3
- a) a selectin;
 - b) a selectin ligand other than a CD34 polypeptide;
 - c) an antibody capable of binding a selectin or a selectin ligand other than a CD34 polypeptide;
 - d) an integrin;
 - e) an integrin ligand; and
 - f) an antibody capable of binding an integrin or an integrin ligand[; and
 - g) a non-protein antagonist of L-selectin-CD34 interaction].

In claim 11, line 1; and claim 12, line 1, please replace "2" by --1--.

Please amend claim 26 and follows:

Q4
26. (Amended) A pharmaceutical composition for the treatment of L-selectin-mediated inflammation comprising a therapeutically effective amount of an isolated, purified CD34 [polypeptide or an anti-CD34 antibody] glycoprotein having the endothelial glycoform of native CD34 in admixture with a suitable pharmaceutically acceptable vehicle.

Remarks

The foregoing amendments in the specification are corrections of obvious typographical errors or are of formal nature, and do not introduce new matter into the specification. Similarly, the amendments in the claims are fully supported by the specification and claims as